Immune checkpoint inhibitor-induced diabetic ketoacidosis:Report of one case and literature review
Objective:To summarize the clinical presentations of patients complicated with type1 diabetes mellitus(T1DM)following immune checkpoint inhibitor therapy(ICIT1D)for improving understanding of this rare complication.Methods:Observation and analysis were conducted in one case of ICIT1D regarding the clinical data,laboratory findings,and follow-up outcomes,with relevant literatures reviewed.Results:T1DM for the patient was presumably induced by the programmed death receptor-1(PD-1)inhibitor karelizumab.The disease exhibited a rapid onset,with diabetic ketoacidosis(DKA)as the initial presentation.Laboratory evaluations revealed low insulin C-peptide levels and negative islet autoantibodies.The patient's condition was improved following interventions including rehydration,glucose-lowering,and acid-correcting therapies.Conclusion:Patients without history of diabetes that occurs soon after immune checkpoint inhibitor therapy,particularly presenting DKA at first,should be alerted to be potential ICIT1D.
immune checkpoint inhibitortype 1 diabetes mellitusdiabetic ketoacidosisprogrammed death ligand 1camrelizumab
万方数据
维普
